STOCK TITAN

Scisparc - SPRC STOCK NEWS

Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.

Comprehensive Overview of SciSparc Ltd (SPRC)

SciSparc Ltd is a specialty clinical‐stage pharmaceutical company that leverages cutting‐edge cannabinoid technologies to develop innovative immunotherapy products and address central nervous system disorders. At its core, SciSparc focuses on the development of therapies derived from cannabinoid molecules, incorporating advanced biotechnology, immunotherapy, and clinical research methodologies. This dual‐focused enterprise operates across two distinct segments: one dedicated to clinical drug development and regulatory pathways, and another which drives the online sale of hemp-based consumable products.

Clinical-Stage Drug Development

The company’s primary business revolves around its clinical-stage drug development programs. SciSparc employs a portfolio based on both THC and non-psychoactive CBD compounds to create novel treatments for disorders such as Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus. Utilizing a rigorous, research-driven approach, the company undertakes controlled clinical trials designed to evaluate drug efficacy, safety, and tolerability. With its IND applications and approvals for advanced clinical programs, SciSparc demonstrates its commitment to meeting stringent regulatory standards and addressing unmet medical needs in its target therapeutic areas.

Innovative Technology and Intellectual Property

SciSparc’s market positioning is strengthened by its robust portfolio of patents and proprietary technologies. The company’s innovations in cannabinoid pharmaceuticals are not only geared towards improving treatment outcomes but also distinguishing its offerings from traditional therapies. By investing in advanced research platforms, including computational drug discovery and predictive artificial intelligence models, SciSparc is able to screen and identify promising molecular candidates for further development. This technological prowess, combined with a clear focus on regulatory compliance and scientific excellence, forms the backbone of its strategic differentiation.

Online Sales and Hemp-Based Consumer Products

In addition to its core clinical operations, SciSparc diversifies its business model through a reportable segment that manages the online sale of a wide range of hemp-derived products. These products, which include hemp gummies, oil capsules, topical gels, creams for beauty and hair treatments, and other nutraceutical items, are manufactured domestically in the United States. This segment not only leverages SciSparc’s expertise in cannabinoid science but also capitalizes on the growing consumer demand for hemp-based nutritional and wellness products.

Strategic Positioning in a Competitive Landscape

SciSparc operates in a competitive and dynamic landscape where rigorous clinical research, robust intellectual property protection, and diversified revenue streams are critical. The company’s dual approach—pursuing breakthrough therapies through detailed clinical trials while also serving a broad consumer market with hemp-based products—allows it to mitigate risk and explore multiple avenues for value creation. By maintaining adherence to high standards of scientific inquiry and regulatory diligence, SciSparc reinforces its position as a trusted and innovative entity within the pharmaceutical and nutraceutical industries.

Expertise, Experience, and Trustworthiness

The expertise demonstrated by SciSparc’s team of senior executives and scientists adds a further layer of credibility to its endeavors. The company’s rigorous research protocols, combined with its strategic investments in cutting-edge technology and regulatory expertise, underscore its commitment to scientific excellence and long-term value creation. This methodical, research-intensive approach not only builds trust among stakeholders but also serves as a foundation for advancing next-generation therapies in areas that have long presented clinical challenges.

Conclusion

In summary, SciSparc Ltd exemplifies a forward-thinking pharmaceutical enterprise that effectively blends innovative drug development with consumer-oriented online sales. Its robust portfolio in cannabinoid-based immunotherapies, supported by extensive intellectual property and strategic clinical trials, positions it uniquely within a competitive market landscape. Whether addressing central nervous system disorders or fulfilling the growing consumer demand for hemp products, SciSparc’s dual business model represents a comprehensive and balanced approach to modern pharmaceutical innovation.

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) has announced the submission of a new patent application to the USPTO for a novel composition combining Palmitoylethanolamide (PEA), the active ingredient in their CannAmide™ product, with Clearmind Medicine's MEAI compound. This innovative formulation aims to treat metabolic syndrome and obesity.

The patent application is part of an ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) and was developed in conjunction with Professor Joseph Tam from the Hebrew University. This marks the thirteenth patent application filed under this partnership, targeting various disorders including alcohol use disorder and cocaine addiction.

The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a 10.0% CAGR. With obesity affecting 41.9% of U.S. adults aged 20 and over, this new treatment could address a significant health concern and market opportunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
-
Rhea-AI Summary

SciSparc announced signing a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals to Miza III Ventures. Valued at $11.6 million, the assets will be exchanged for 63.3 million Miza shares and up to 48 million contingent rights. The deal's final terms will determine SciSparc's controlling stake in Miza, estimated between 75% and 84.53%. The transaction aligns with SciSparc's strategy to enhance shareholder value and follows a merger agreement with AutoMax Motors. Key portfolio assets include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
Rhea-AI Summary

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced the European Patent Office granted its patent application for 'Compositions and Methods of Potentiating Antimicrobials'. This patent, which complements a similar U.S. patent, enhances SciSparc's intellectual property portfolio and competitive edge in the pharmaceutical industry. The patent covers pharmaceutical compositions combining antibiotics and cannabinoids, potentially addressing antimicrobial resistance. SciSparc is actively expanding its intellectual property globally, with recent patents in Canada and Europe, reflecting its commitment to innovation. The company’s portfolio now spans major markets including the U.S., Europe, Japan, Australia, and Israel, encompassing nine patent families and two trademarks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
News
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) announces a merger agreement with AutoMax Motors , a leading vehicle importer in Israel. The deal entails SciSparc acquiring 100% of AutoMax, forming a new Israeli subsidiary. Shareholders will hold 50.01% of the Combined Company post-merger. The Acquisition aims to maximize shareholder value following a strategic review in 2022. The deal is subject to regulatory approvals and shareholder agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary
SciSparc announces collaboration with Clearmind Medicine Inc. for novel therapy to treat depression. Clearmind submits patent application for MEAI compound combined with SciSparc's CannAmide™. Global depression and anxiety disorders treatment market expected to reach USD 41.83 billion by 2034.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
-
Rhea-AI Summary
SciSparc announces MitoCareX Bio's successful identification of potential anti-cancer small molecules through advanced drug discovery platform and in-vitro screening systems, leading to the development of a predictive AI model for more efficient drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) secures a patent for its core technology combining cannabinoids and n-acylethanolamines from the Canadian Intellectual Property Office. The patent aims to enhance the safety of cannabinoids with low dosages while maintaining therapeutic benefits, supporting the company's innovative technologies for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has dosed the first patient in a clinical trial for Autism Spectrum Disorder in pediatric patients. The trial is for SCI-210 at Soroka Medical Center, marking a crucial advancement in treating rare diseases of the central nervous system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
-
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces MitoCareX Bio's progress in utilizing a predictive AI model to identify potential anti-cancer treatments. MitoCareX screened millions of small molecules, confirming anti-cancer activity through in-vitro testing. The company aims to enhance drug discovery efficiency by developing a predictive AI model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
Rhea-AI Summary
SciSparc Ltd. announces enrollment of the first patient in a clinical trial for SCI-210, a treatment for children with autism spectrum disorder. The company aims to address the unmet need for efficient and safe treatments in this area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags

FAQ

What is the current stock price of Scisparc (SPRC)?

The current stock price of Scisparc (SPRC) is $0.2705 as of April 4, 2025.

What is the market cap of Scisparc (SPRC)?

The market cap of Scisparc (SPRC) is approximately 3.1M.

What is the primary focus of SciSparc Ltd?

SciSparc Ltd is primarily focused on developing cannabinoid-based immunotherapies to treat central nervous system disorders through rigorous clinical-stage drug development.

How does SciSparc generate its revenue?

The company generates revenue through two main segments: clinical-stage pharmaceutical research and development, and online sales of a variety of hemp-derived nutraceutical and wellness products.

What types of disorders is SciSparc targeting?

SciSparc is targeting several CNS disorders including Tourette Syndrome, Alzheimer’s disease with agitation, autism spectrum disorder, and status epilepticus, among other conditions.

How does SciSparc differentiate itself in the pharmaceutical industry?

SciSparc differentiates itself through its proprietary portfolio of cannabinoid-based technologies, its advanced clinical trials, and its dual business model that spans both innovative drug development and consumer hemp products.

What role do patents and proprietary technologies play at SciSparc?

The company's extensive portfolio of patents and proprietary technologies underscores its commitment to innovation and regulatory compliance, providing a competitive edge in drug discovery and development.

How does SciSparc manage regulatory compliance?

SciSparc adheres to strict regulatory standards by conducting controlled clinical trials, obtaining IND approvals, and ensuring that its hemp-based products are manufactured under stringent quality controls in the United States.

What market segments does SciSparc serve?

SciSparc serves both the pharmaceutical market with its drug development programs and the consumer market through its online distribution of hemp-based nutraceutical and wellness products.

How experienced is the management team at SciSparc?

SciSparc is led by a team of experienced senior executives and scientists, whose expertise in fields such as clinical research, regulatory affairs, and biotechnology supports the company’s innovative approach and enhances its trustworthiness.
Scisparc

Nasdaq:SPRC

SPRC Rankings

SPRC Stock Data

3.06M
10.83M
0%
1.21%
0.62%
Biotechnology
Healthcare
Link
Israel
Tel Aviv